FLUTICASONE PROPIONATE

Search structure
Trade Names:
Synonyms:
Status: Approved (1990)
Entry Type: Small molecule
Molecule Category: Salt
UNII: O2GMZ0LF5W
Parent Compound: FLUTICASONE

Structure
InChI Key WMWTYOKRWGGJOA-CENSZEJFSA-N
Smile CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
InChI
InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C25H31F3O5S
Molecular Weight 500.58
AlogP 4.43
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 4.0
Polar Surface Area 80.67
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 34.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Glucocorticoid receptor agonist
Primary Target
Glucocorticoid receptor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Hydrolase
- - - - 7.634
Enzyme Transferase
- - - -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 1
0.7-1.09 0.04-0.9 - - -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 2
- 149 - - -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 3
- 21 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Nasal Polyps 4 D009298 ClinicalTrials
Eosinophilic Esophagitis 3 D057765 ClinicalTrials
Bronchiolitis Obliterans 3 D001989 ClinicalTrials
Sinusitis 3 D012852 ClinicalTrials
Respiratory Sounds 3 D012135 ClinicalTrials
Chronic Disease 3 D002908 ClinicalTrials
Rhinitis, Allergic, Perennial 3 D012221 ClinicalTrials
Severe Acute Respiratory Syndrome 2 D045169 ClinicalTrials
Adenomatous Polyposis Coli 2 D011125 ClinicalTrials
Carcinoma, Bronchogenic 2 D002283 ClinicalTrials
Bronchiolitis 2 D001988 ClinicalTrials
Rhinitis 2 D012220 ClinicalTrials
Blepharitis 2 D001762 ClinicalTrials

Related Entries

Scaffolds

Parent
Mixture
Mixture

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Injury, poisoning and procedural complications
18.5
Respiratory, thoracic and mediastinal disorders
18.32
General disorders and administration site conditions
12.62
Nervous system disorders
7.05
Gastrointestinal disorders
5.59
Cardiac disorders
4.69
Product issues
4.49
Psychiatric disorders
4.01
Vascular disorders
3.71
Infections and infestations
3.56
Immune system disorders
3.0
Skin and subcutaneous tissue disorders
2.34
Musculoskeletal and connective tissue disorders
2.15

Cross References

Resources Reference
CAS NUMBER 80474-14-2
ChEBI 31441
ChEMBL CHEMBL1473
DrugBank DB00588
DrugCentral 1225
FDA SRS O2GMZ0LF5W
Human Metabolome Database HMDB14726
Guide to Pharmacology 7080
PharmGKB PA449686
PubChem 444036
SureChEMBL SCHEMBL4068
ZINC ZINC000003920027
CONTENTS